Monday 6-9-2014 Merck & Company (MRK) $MRK opened
Post# of 151
Posted On: 06/09/2014 6:36:09 PM
Monday 6-9-2014 Merck & Company (MRK) $MRK opened at 57.47 hitting the high price of 57.97 and a day low of 57.24 with a total volume of 8,082,898. MRK had a previous close of 57.85 and has been seeing an average volume of 7,754,028.
Overall Average: 80% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
It's a Placebo, It's a Drug, Wait: It's Both
Brian Orelli, The Motley Fool - Motley Fool - 5 mins ago
In an astonishing move, AFFiRiS issued a press release last week touting AD04 as "the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients." What is AD04? It's the placebo used in... (full story)
Is Pfizer's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - 5 mins ago
Pfizer is one of the globe's biggest drugmakers, and its stock is a staple in dividend portfolios. However, patent expiration of key drugs has shaved billions off its top line, putting pressure on Pfizer to use its substantial cash position to... (full story)
Why Merck's Buyout of Idenix Pharmaceuticals Is a Mistake
George Budwell, The Motley Fool - Motley Fool - 30 mins ago
In something of a surprising move, Merck & Co. announced today that it is buying Idenix Pharmaceuticals in a deal that comes at a whopping 238% premium compared to the company's closing price on Friday. Specifically, Merck is paying $3.85... (full story)
Business Highlights
By The Associated Press - AP - 48 mins ago
___ (full story)
Why Idenix Pharmaceuticals, Achillion Pharmaceuticals, and Hittite Microwave Are Today's 3 Best Stoc
Sean Williams, The Motley Fool - Motley Fool - 1 hr 10 mins ago
Another day, another record intraday high for the broad-based S&P 500 which continues to be unstoppable since its mini-April swoon. Although no economic data helped lead the S&P 500 to a fresh all-time intraday high near 1,956, a... (full story)
Stock market ekes out another record high
By MATTHEW CRAFT - AP - 58 mins ago
NEW YORK (AP) — Call it the ho-hum market. Another day, another record high. (full story)
Merck's $3.9 Billion Splash Into the Hepatitis C Market
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs ago
On the heels of uncorking a $14 billion asset sale of its consumer care business to Bayer , Merck is inking a deal to acquire Idenix Pharmaceuticals . The $3.9 billion acquisition barely dents Merck's balance sheet, which sports cash and... (full story)
Stocks Gain In Mixed Trade; Chips Soar, Keurig Caves
at Investor's Business Daily - 2 hrs 11 mins ago
Stocks raked up narrow gains Monday as the S&P 500 pushed to a fourth consecutive record close. The tech sector started strong and helped the Nasdaq to a 0.3% gain. The Dow Jones industrial average and the S&P 500 clocked gains of 0.1% apiece. The... (full story)
No News Is OK News as Markets Hold Onto Record Gains
at The Street - 2 hrs 22 mins ago
With a busy week of economic data behind us, U.S. markets were little changed Monday in the absence of any market-moving catalyst. (full story)
Why Idenix Pharmaceuticals (IDIX) Exploded to a One-Year High Today (Update)
at The Street - 2 hrs 30 mins ago
Idenix Pharmaceuticals (IDIX) shares exploded to a new 52-week high of $24.21 on Monday amid news that Merck (MRK) would purchase the biotechnology company for $3.85 billion. (full story)
Who is Buying Small Caps at P/E 84? - Real Time Insight
Kevin Cook - Zacks Investment Research - Mon Jun 09, 2:31PM CDT
The bull market leader is staging a big comeback with new highs in sight (full story)
Merck to pay $3.85B for hepatitis C drug developer
By LINDA A. JOHNSON - AP - 58 mins ago
TRENTON, N.J. (AP) — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions. (full story)
Why Achillion Pharmaceuticals Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 09, 1:41PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a... (full story)
Merck's Huge Hep C Buy Shakes Up the Dow
Dan Carroll, The Motley Fool - Motley Fool - Mon Jun 09, 1:36PM CDT
The major U.S,. indieces have pulled back from earlier spikes, with the Dow Jones Industrial Average just under breakeven as of 2:30 p.m. EDT and its member stocks split starting to lean more heavily toward losers for the day . Merck led... (full story)
Why Idenix Pharmaceuticals, Inc. Shares Skyrocketed More Than 230%
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 09, 1:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idenix Pharmaceuticals , a clinical-stage... (full story)
Tyson's $8.5 Bil Hillshire Deal Tops Monday's M&As
at Investor's Business Daily - Mon Jun 09, 1:03PM CDT
Tyson Foods emerged as the winner in a bidding war for Hillshire Brands by offering $63 a share, or $8.5 billion, topping Pilgrim's Pride's (PPC) offer by $1 billion, in one of a series of deals announced Monday. But Tyson Foods (TSN), the largest... (full story)
IDENIX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Mon Jun 09, 12:28PM CDT
Rigrodsky & Long, P.A.: (full story)
Merck Scoops Up Idenix in $3.85B Buyout
Ben Fidler, The Motley Fool - Motley Fool - Mon Jun 09, 12:03PM CDT
Idenix Pharmaceuticals nearly became a footnote in the hepatitis C drug race a few years ago when Bristol-Myers Squibb's buyout of Inhibitex imploded, kick-starting a series of events that led the FDA to slap clinical holds on two of the Cambridge,... (full story)
Fitch: Merck Buy of Idenix Underscores Therapeutic Add Focus
Business Wire - Mon Jun 09, 10:53AM CDT
Additional mergers and acquisitions (M&A) activity in the pharmaceutical sector highlights an increased focus on large branded drugmakers seeking to fill gaps or expand into various therapeutic areas, according to Fitch Ratings. Merck & Co. (MRK) Monday announced it had agreed to buy Idenix Pharmaceuticals Inc. for approximately $3.85 billion in order to amplify options for treatment of hepatitis C (HCV). (full story)
Overall Average: 80% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
It's a Placebo, It's a Drug, Wait: It's Both
Brian Orelli, The Motley Fool - Motley Fool - 5 mins ago
In an astonishing move, AFFiRiS issued a press release last week touting AD04 as "the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients." What is AD04? It's the placebo used in... (full story)
Is Pfizer's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - 5 mins ago
Pfizer is one of the globe's biggest drugmakers, and its stock is a staple in dividend portfolios. However, patent expiration of key drugs has shaved billions off its top line, putting pressure on Pfizer to use its substantial cash position to... (full story)
Why Merck's Buyout of Idenix Pharmaceuticals Is a Mistake
George Budwell, The Motley Fool - Motley Fool - 30 mins ago
In something of a surprising move, Merck & Co. announced today that it is buying Idenix Pharmaceuticals in a deal that comes at a whopping 238% premium compared to the company's closing price on Friday. Specifically, Merck is paying $3.85... (full story)
Business Highlights
By The Associated Press - AP - 48 mins ago
___ (full story)
Why Idenix Pharmaceuticals, Achillion Pharmaceuticals, and Hittite Microwave Are Today's 3 Best Stoc
Sean Williams, The Motley Fool - Motley Fool - 1 hr 10 mins ago
Another day, another record intraday high for the broad-based S&P 500 which continues to be unstoppable since its mini-April swoon. Although no economic data helped lead the S&P 500 to a fresh all-time intraday high near 1,956, a... (full story)
Stock market ekes out another record high
By MATTHEW CRAFT - AP - 58 mins ago
NEW YORK (AP) — Call it the ho-hum market. Another day, another record high. (full story)
Merck's $3.9 Billion Splash Into the Hepatitis C Market
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs ago
On the heels of uncorking a $14 billion asset sale of its consumer care business to Bayer , Merck is inking a deal to acquire Idenix Pharmaceuticals . The $3.9 billion acquisition barely dents Merck's balance sheet, which sports cash and... (full story)
Stocks Gain In Mixed Trade; Chips Soar, Keurig Caves
at Investor's Business Daily - 2 hrs 11 mins ago
Stocks raked up narrow gains Monday as the S&P 500 pushed to a fourth consecutive record close. The tech sector started strong and helped the Nasdaq to a 0.3% gain. The Dow Jones industrial average and the S&P 500 clocked gains of 0.1% apiece. The... (full story)
No News Is OK News as Markets Hold Onto Record Gains
at The Street - 2 hrs 22 mins ago
With a busy week of economic data behind us, U.S. markets were little changed Monday in the absence of any market-moving catalyst. (full story)
Why Idenix Pharmaceuticals (IDIX) Exploded to a One-Year High Today (Update)
at The Street - 2 hrs 30 mins ago
Idenix Pharmaceuticals (IDIX) shares exploded to a new 52-week high of $24.21 on Monday amid news that Merck (MRK) would purchase the biotechnology company for $3.85 billion. (full story)
Who is Buying Small Caps at P/E 84? - Real Time Insight
Kevin Cook - Zacks Investment Research - Mon Jun 09, 2:31PM CDT
The bull market leader is staging a big comeback with new highs in sight (full story)
Merck to pay $3.85B for hepatitis C drug developer
By LINDA A. JOHNSON - AP - 58 mins ago
TRENTON, N.J. (AP) — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions. (full story)
Why Achillion Pharmaceuticals Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 09, 1:41PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a... (full story)
Merck's Huge Hep C Buy Shakes Up the Dow
Dan Carroll, The Motley Fool - Motley Fool - Mon Jun 09, 1:36PM CDT
The major U.S,. indieces have pulled back from earlier spikes, with the Dow Jones Industrial Average just under breakeven as of 2:30 p.m. EDT and its member stocks split starting to lean more heavily toward losers for the day . Merck led... (full story)
Why Idenix Pharmaceuticals, Inc. Shares Skyrocketed More Than 230%
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 09, 1:17PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Idenix Pharmaceuticals , a clinical-stage... (full story)
Tyson's $8.5 Bil Hillshire Deal Tops Monday's M&As
at Investor's Business Daily - Mon Jun 09, 1:03PM CDT
Tyson Foods emerged as the winner in a bidding war for Hillshire Brands by offering $63 a share, or $8.5 billion, topping Pilgrim's Pride's (PPC) offer by $1 billion, in one of a series of deals announced Monday. But Tyson Foods (TSN), the largest... (full story)
IDENIX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Mon Jun 09, 12:28PM CDT
Rigrodsky & Long, P.A.: (full story)
Merck Scoops Up Idenix in $3.85B Buyout
Ben Fidler, The Motley Fool - Motley Fool - Mon Jun 09, 12:03PM CDT
Idenix Pharmaceuticals nearly became a footnote in the hepatitis C drug race a few years ago when Bristol-Myers Squibb's buyout of Inhibitex imploded, kick-starting a series of events that led the FDA to slap clinical holds on two of the Cambridge,... (full story)
Fitch: Merck Buy of Idenix Underscores Therapeutic Add Focus
Business Wire - Mon Jun 09, 10:53AM CDT
Additional mergers and acquisitions (M&A) activity in the pharmaceutical sector highlights an increased focus on large branded drugmakers seeking to fill gaps or expand into various therapeutic areas, according to Fitch Ratings. Merck & Co. (MRK) Monday announced it had agreed to buy Idenix Pharmaceuticals Inc. for approximately $3.85 billion in order to amplify options for treatment of hepatitis C (HCV). (full story)
(0)
(0)